β-blockers as endocrine disruptors: The potential effects of human β-blockers on aquatic organisms

Journal of Experimental Zoology Part A: Ecological Genetics and Physiology

Volumn 315 A, Issue 5, 2011, Pages 251-265

  Massarsky, Andrey ^a   Trudeau, Vance L ^a   Moon, Thomas W ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOCRINE DISRUPTOR; GLUCOSE; INSULIN; METOPROLOL; NADOLOL; PROPRANOLOL;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; FISH; GLUCONEOGENESIS; GLYCOGENOLYSIS; LIPOLYSIS; METABOLISM; MOLLUSC; MUSCLE CONTRACTION; REVIEW; SECRETION; SPECIES DIFFERENCE; WATER POLLUTANT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATENOLOL; ENDOCRINE DISRUPTORS; FISHES; GLUCONEOGENESIS; GLUCOSE; GLYCOGENOLYSIS; INSULIN; LIPOLYSIS; METOPROLOL; MOLECULAR STRUCTURE; MOLLUSCA; MUSCLE CONTRACTION; NADOLOL; PROPRANOLOL; SPECIES SPECIFICITY; WATER POLLUTANTS, CHEMICAL;

INVERTEBRATA; MAMMALIA; MOLLUSCA;

EID: 79955669556     PISSN: 19325223     EISSN: 19325231     Source Type: Journal    
DOI: 10.1002/jez.672     Document Type: Review

References (104)

1. Adamo SA. 2008. Norepinephrine and octopamine: linking stress and immune function across phyla. Invert Survival J 5:12-19.
2. Angulo J, Wright HM, Cuevas P, González-Corrochano R, Fernández A, Cuevas B, La Fuente JM, Gupta S, Sáenz de Tejada I. 2010. Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling. J Sex Med 7:2681-2697.
3. 2-adrenoceptors in the adult zebrafish brain (Danio rerio). J Comp Neurol 518:1418-1441.
4. Aris-Brosou S, Chen X, Perry SF, Moon TW. 2009. Timing of the functional diversification of α- and β-adrenoceptors in fish and other vertebrates. Ann NY Acad Sci 1163:343-347.
5. - secretion in seawater fish (Dicentrarchus labrax) gill respiratory cells in primary culture. J Physiol 516:353-363.
6. Bakris GL, Bell DSH, Fonseca V, Katholi R, McGill J, Phillips R, Raskin P, Wright Jr JT, Iyengar M, Holeslaw T, Anderson KM. 2005. The rationale and design of the glycemic effects in diabetes mellitus carvedilol-metoprolol comparison in hypertensives (GEMINI) trial. J Diabetes Complicat 19:74-79.
7. Bervoets L, Voets J, Covaci A, Chu S, Qadah D, Smolders R, Schepens P, Blust R. 2005. Use of transplanted Zebra mussels (Dreissena polymorpha) to assess the bioavailability of microcontaminants in Flemish surface waters. Environ Sci Technol 39:1492-1505.
8. Blais V, Bounif N, Dubé F. 2010. Characterisation of a novel octopamine receptor expressed in the surf clam Spisula solidissima. Gen Comp Endocrinol 167:215-227.
9. Brodde OE. 2007. β-adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. NS Arch Pharmacol 374:361-372.
10. Buhler DR, Buhler J-LW. 1998. Rainbow trout cytochrome P450s: purification, molecular aspects, metabolic activity, induction and role in environmental monitoring. Comp Biochem Physiol 121C:107-137.
11. Caliman FA, Gavrilescu M. 2009. Pharmaceuticals, personal care products and endocrine disrupting agents in the environment-a review. CSAW 37:277-303.
12. Campbell AK, Wann KT, Matthews SB. 2004. Lactose causes heart arrhythmia in the water flea Daphnia pulex. Comp Biochem Physiol 139B:225-234.
13. Chang JP, Peter RE. 1984. Influences of norepinephrine and α-adrenergic mechanisms on gonadotropin secretion in female goldfish, Carassius auratus. Gen Comp Endocrinol 55:89-95.
14. Chang JP, Van Goor F, Acharya S. 1991. Influences of norepinephrine, and adrenergic agonists and antagonists on gonadotropin secretion from dispersed pituitary cells of goldfish, Carassius auratus. Neuroendocrinol 54:202-210.
15. 1-adrenoceptor gene family: insights from rainbow trout (Oncorhynchus mykiss). Physiol Genomics 32:142-153.
16. Colborn T, Dumanoski D, Peterson MJ. 1997. Our stolen future: how are we threatening our fertility, intelligence, and survival? New York, NY: Plume Book, Penguin Group.
17. Corcoran J, Winter MJ, Tyler CR. 2010. Pharmaceuticals in the aquatic environment: A critical review of the evidence for health effects in fish. Crit Rev Toxicol 40:287-304.
18. Dugan SG, Chen X, Nickerson JG, Montpetit CJ, Moon TW. 2008. Regulation of the black bullhead hepatic β-adrenoceptors. Comp Biochem Physiol 149B:265-274.
19. Dzialowski EM, Turner PK, Brooks BW. 2006. Physiological and reproductive effects of beta adrenergic receptor antagonists in Daphnia magna. Arch Environ Contam Toxicol 50:503-510.
20. Erdmann E. 2009. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J 11:A21-A25.
21. Fabbri E, Capuzzo A. 2010. Cyclic AMP signaling in bivalve molluscs: an overview. J Exp Zool (Mol Dev Evol) 313A:179-200.
22. Fabbri E, Gambarotta A, Moon TW. 1995. Adrenergic signaling and second messenger production in hepatocytes of two fish species. Gen Comp Endocrinol 99:114-124.
23. Fabbri E, Capuzzo A, Moon TW. 1998. The role of circulating catecholamines in the regulation of fish metabolism: an overview. Comp Biochem Physiol 120C:177-192.
24. Falcón J, Thibault C, Martin C, Brun-Marmillon J, Claustrat B, Collin J-P. 1991. Regulation of melatonin production by catecholamines and adenosine in a photoreceptive pineal organ. An in vitro study in the pike and trout. J Pineal Res 11:123-134.
25. Franzellitti S, Buratti S, Valbonesi P, Capuzzo A, Fabbri E. 2011. The β-blocker propranolol affects cAMP-dependent signaling and induces the stress response in Mediterranean mussels, Mytilus galloprovincialis. Aquat Toxicol 101:299-308.
26. Frishman WH. 2008. β-Adrenergic blockers: a 50-year historical perspective. Am J Therap 15:565-576.
27. Frishman WH, Alwarshetty M. 2002. β-Adrenergic blockers in systemic hypertension-pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 41:505-516.
28. Gerhardt CC, Bakker RA, Piek GJ, Planta RJ, Vreugdenhil E, Leysen JE, Van Heerikhuizen H. 1997. Molecular cloning and pharmacological characterization of a molluscan octopamine receptor. Mol Pharmacol 51:293-300.
29. Gerwick L, Demers NE, Bayne CJ. 1999. Modulation of stress hormones in rainbow trout by means of anesthesia, sensory deprivation and receptor blockade. Comp Biochem Physiol 124:329-334.
30. Gether U. 2000. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21:90-113.
31. Giltrow E, Eccles PD, Winter MJ, McCormack PJ, Rand-Weaver M, Hutchinson TH, Sumpter JP. 2009. Chronic effects assessment and plasma concentrations of the β-blocker propranolol in fathead minnows (Pimephales promelas). Aquat Toxicol 95:195-202.
32. Gloriam DEI, Bjarnadóttir TK, Schiöth HB, Fredriksson R. 2005. High species variation within the repertoire of trace amine receptors. Ann NY Acad Sci 1040:323-327.
33. Gosling E. 2003. Bivalve molluscs-biology, ecology and culture. Malden, MA: Fishing New Books. 7-39, 87p.
34. Gray CL, Ndefo UA. 2008. Nebivolol: a new antihypertensive agent. Am J Health Syst Pharmacol 65:1125-1133.
35. Gregalis KC, Powers SP, Heck Jr KL. 2008. Restoration of oyster reefs along a bio-physical gradient in Mobile Bay, Alabama. J Shellfish Res 27:1163-1169.
36. Grizzle RE, Greene JK, Coen LD. 2008. Seston removal by natural and constructed intertidal eastern oyster (Crassostrea virginica) reefs: a comparison with previous laboratory studies, and the value of in situ methods. Estuar Coast 31:1208-1220.
37. Harris DM, Cohn HI, Pesant S, Eckhart AD. 2008. GPCR signalling in hypertension: role of GRKs. Clin Sci 115:79-89.
38. Hemmelgarn BR, Chen G, Walker R, McAlister FA, Quan H, Tu K, Khan N, Campbell N. 2008. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol 24:507-512.
39. Hubbard PC, Balment RJ, McCrohan CR. 1996. Adrenergic receptor activation hyperpolarizes the caudal neurosecretory cells of the flounder, Platichthys flesus. J Neuroendocrinol 8:153-159.
40. Hubbard PC, Barata EN, Canário AVM. 2003. Olfactory sensitivity to catecholamines and their metabolites in the goldfish. Chem Senses 28:207-218.
41. Huggett DB, Brooks BW, Peterson B, Schlenk D. 2002. Toxicity of select beta adrenergic receptor-blocking pharmaceuticals (β-blockers) on aquatic organisms. Arch Environ Con Tox 43:229-235.
42. Huggett DB, Benson WH, Chipman K, Cook JC, Gray LE, Kinter LB, Meyerhoff RD, Trudeau VL. 2005. Role of mammalian data in determining pharmaceutical responses in aquatic species. In: Williams RT, editor. Human Pharmaceuticals-assessing the impacts on aquatic ecosystems. Snowbird, Utah: SETAC. p 149-182.
43. IPCS (International Programme on Chemical Safety). 2002. Global assessment of the state-of-the-science of endocrine disruptors-an assessment prepared by an expert group on behalf of the World Health Organization, the International Labour Organization, and The United Nations Environment Programme. p. 2. Eds. Damstra T, Barlow S, Bergman A, Kavlock R, and Van Der Kraak G.
44. Kaneko M. 2007. Sympathetic nervous system research developments. Preface.New York, NY: Science Publishers Inc.
45. Khafizov K, Lattanzi G, Carloni P. 2009. G protein inactive and active forms investigated by simulation methods. Proteins 75:919-930.
46. Knacker T, Metcalfe C. 2010. Introduction to the special issue on environmental rich assessment of pharmaceuticals. Integr Environ Assess Manag 6:511-513.
47. Kondo H, Nifuji A, Takeda S, Ezura Y, Rittling SR, Denhardt DT, Nakashima K, Karsenty G, Noda M. 2005. Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem 280:30192-30200.
48. Küster A, Alder AC, Escher BI, Duis K, Fenner K, Garric J, Hutchinson TH, Lapen DR, Péry A, Römbke J, Snape J, Ternes T, Topp E, Wehrhan A, Knacker T. 2010. Environmental risk assessment of human pharmaceuticals in the European Union: a case study with the β-blocker atenolol. Integr Environ Assess Manag 6:514-523.
49. Lacoste A, Malham SK, Cueff A, Poulet SA. 2001a. Norepinephrine modulates oyster hemocyte phagocytosis via a β-adrenergic receptor-cAMP signaling pathway. Gen Comp Endocrinol 122:252-259.
50. Lacoste A, Malham SK, Cueff A, Jalabert F, Gélébart F, Poulet SA. 2001b. Evidence for a form of adrenergic response to stress in the mollusk Crassostrea gigas. J Exp Biol 204:1247-1255.
51. Lacoste A, Malham SK, Gélébart F, Cueff A, Poulet S. 2002. Stress-induced immune changes in the oyster Crassostrea gigas. Dev Comp Immunol 26:1-9.
52. Lama PJ. 2002. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol 143:749-760.
53. Larsson DGJ, Fredriksson S, Sandblom E, Paxeus N, Axelsson M. 2006. Is the heart rate in fish a sensitive indicator to evaluate acute effects of β-blockers in surface water? Environ Toxicol Pharmacol 22:338-340.
54. 2 adrenoreceptor and interactions with dopamine and salmon gonadotropin-releasing hormone. J Neuroendocrinol 12:311-322.
55. 2-adrenoceptor agonist medetomidine. Mol Pharmacol 78:237-248.
56. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. 2004. Expert consensus document on β-adrenergic receptor blockers-the task force on beta-blockers of the European Society of Cardiology. Eur Heart J 25:1341-1362.
57. Lortie MB, Moon TW. 2003. The rainbow trout skeletal muscle β-adrenergic system: characterization and signaling. Am J Physiol Reg Integr Comp Physiol 284:R689-R697.
58. Ma Y-C, Huang J, Ali S, Lowry W, Huang X-Y. 2000. Src tyrosine kinase is a novel direct effector of G proteins. Cell 102:635-646.
59. Ma L, Li D, Wang J, He J, Yin Z. 2009. Effects of adrenergic agonists on the extrahepatic expression of vitellogenin Ao1 in heart and brain of the Chinese rare minnow (Gobiocypris rarus). Aquat Toxicol 91:19-25.
60. Magnoni L, Weber J-M. 2008. In vivo regulation of rainbow trout lipolysis by catecholamines. J Exp Biol 211:2460-2466.
61. Malenfant D, Catton M, Pope JE. 2009. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology 48:791-795.
62. Matthiessen P. 2008. An assessment of endocrine disruption in mollusks and the potential for developing internationally standardized mollusk life cycle test guidelines. Integr Environ Assess Manag 4:274-284.
63. Mehvar R, Brocks DR. 2001. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Sci 4:185-200.
64. Merck Index. 2009. 14th edition.
65. Mersmann HJ. 1998. Overview of the effects of β-adrenergic receptor agonists on animal growth including mechanisms of action. J Anim Sci 76:160-172.
66. Michel MC, Rump LC. 1996. α-Adrenergic regulation of human renal function. Fund Clin Pharmacol 10:493-503.
67. Mo C, Neilson B. 1994. Standardization of oyster soft tissue dry weight measurements. Water Res 28:243-246.
68. Moens AL, Yang R, Watts VL, Barouch LA. 2010. Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system. J Mol Cell Cardiol 48:1088-1095.
69. Mohan S, Campbell NRC. 2008. Hypertension management in Canada: good news, but important challenges remain. Can Med Assoc J 178:1458-1460.
70. Neukirchen M, Kienbaum P. 2008. Sympathetic nervous system-evaluation and importance for clinical general anesthesia. Anesthesiology 109:1113-1131.
71. 2-adrenoceptor from the rainbow trout (Oncorhynchus mykiss)-molecular characterization and pharmacology. Eur J Biochem 265:6465-6472.
72. 3-AR subtype. Am J Physiol Reg Integr Comp Physiol 285:R526-R535.
73. Owen SF, Giltrow E, Huggett DB, Hutchinson TH, Saye J, Winter MJ, Sumpter JP. 2007. Comparative physiology, pharmacology and toxicology of β-blockers: mammals versus fish. Aquat Toxicol 82:145-162.
74. Owen SF, Huggett DB, Hutchinson TH, Hetheridge MJ, Kinter LB, Ericson JF, Sumpter JP. 2009. Uptake of propranolol, a cardiovascular pharmaceutical, from water into fish plasma and its effects on growth and organ biometry. Aquat Toxicol 93:217-224.
75. Perry SF, Bernier NJ. 1999. The acute humoral adrenergic stress response in fish: facts and fiction. Aquaculture 177:285-295.
76. PHAC. 2009a. Cardiovascular disease.
77. PHAC. 2009b. Hypertension facts and figures.
78. Prichard BNC, Owens CWI. 1984. Clinical pharmacology of beta-adrenoceptor blocking drugs. In: Kostis JB, De Felice EA, editors. Beta blockers in the treatment of cardiovascular disease. New York, NY: Raven Press. p 1-56.
79. Quigley JM, Naughton SM. 2002. The interrelation of physicochemical parameters and topological descriptors for a series of β-blocking agents. J Chem Inf Comput Sci 42:976-982.
80. Reid SG, Bernier NJ, Perry SF. 1998. The adrenergic stress response in fish: control of catecholamine storage and release. Comp Biochem Physiol 120C:1-27.
81. Rho JM, Storey TW. 2001. Molecular ontogeny of major neurotransmitter receptor systems in the mammalian central nervous system: norepinephrine, dopamine, serotonin, acetylcholine, and glycine. J Child Neurol 16:271-280.
82. Ritter SL, Hall RA. 2009. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol 10:819-830.
83. Roeder T. 1999. Octopamine in invertebrates. Prog Neurobiol 59:533-561.
84. Roeder T, Seifert M, Kähler C, Gewecke M. 2003. Tyramine and octopamine: antagonistic modulators of behaviour and metabolism. Arch Insect Biochem Physiol 54:1-13.
85. Rottlant J, Ruane NM, Dinis MT, Canario AVM, Power DM. 2006. Intra-adrenal interactions in fish: catecholamines stimulated cortisol release in sea bass (Dicentrarchus labrax L.). Comp Biochem Physiol 143:375-381.
86. Rozec B, Erfanian M, Laurent K, Trochu J-N, Gauthier C. 2009. Nebivolol, a vasodilating selective β1-blocker, is a β3-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 53:1532-1538.
87. Rozenfeld R, Devi K. 2010. Receptor heteromerization and drug discovery. Trends Pharmacol Sci 31:124-130.
88. 2-adrenoceptors in zebrafish: drug effects, mRNA and receptor distributions. J Neurochem 94:1559-1569.
89. Rybin VO, Xu X, Lisanti MP, Steinberg SF. 2000. Differential targeting of β-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. J Biol Chem 275:41447-41457.
90. Smeets WJAJ, González A. 2000. Catecholamine systems in the brain of vertebrates: new perspectives through a comparative approach. Brain Res Rev 33:308-379.
91. Stanley JK, Ramirez AJ, Mottaleb M, Chambliss CK, Brooks BW. 2006. Enantiospecific toxicity of the β-blocker propranolol to Daphnia magna and Pimephales promelas. Environ Toxicol Chem 25:1780-1786.
92. Taherpour AA, Taherpour A, Taherpour Z, Taherpour O. 2009. Relationship study of octanol-water partitioning coefficients and total biodegradation of linear simple conjugates polyene and carotene compounds by use of the Randić index and maximum UV wavelength. Phys Chem Liq 47:349-359.
93. Takeo S, Yamada H, Tanonaka K, Hayashi M, Sunagawa N. 1990. Possible involvement of membrane-stabilizing action in beneficial effect of beta adrenoceptor blocking agents on hypoxic and posthypoxic myocardium. J Pharmacol Exp Ther 254:847-856.
94. + exchange on blood oxygen and carbon dioxide transport in fish. J Exp Zool (Mol Dev Evol) 263:160-175.
95. Triebskorn R, Casper H, Scheil V, Schwaiger J. 2007. Ultrastructural effects of pharmaceuticals (carbamazepine, clofibric acid, metoprolol, diclofenac) in rainbow trout (Oncorhynchus mykiss) and common carp (Cyprinus carpio). Anal Bioanal Chem 387:1405-1416.
96. Trudeau VL, Metcalfe CD, Mimeault C, Moon TW. 2005. Pharmaceuticals in the environment: drugged fish? In: Mommsen TP, Moon TW, editors. Environmental toxicology; biochemistry and molecular biology of fishes, Vol. 6. Amsterdam: Elsevier. p 475-493.
97. Van Raaij MTM, Van den Thillart GEEJM, Vianen GJ, Pit DSS, Balm PHM, Steffens AB. 1996. Substrate mobilization and hormonal changes in rainbow trout (Oncorhynchus mykiss L.) and common carp (Cyprinus carpio L.) during deep hypoxia and subsequent recovery. J Comp Physiol Part B 166:443-452.
98. Wang Z, Nishimura Y, Shimada Y, Umemoto N, Hirano M, Zang L, Oka T, Sakamoto C, Kuroyanagi J, Tanaka T. 2009. Zebrafish β-adrenergic receptor mRNA expression and control of pigmentation. Gene 446:18-27.
99. Wendelaar-Bonga SE. 1997. The stress response in fish. Physiol Rev 77:591-625.
100. Winter MJ, Lillicrap AD, Caunter JE, Schaffner C, Alder AC, Ramil M, Ternes TA, Giltrow E, Sumpter JP, Hutchinson TH. 2008. Defining the chronic impacts of atenolol on embryo-larval development and reproduction in the fathead minnow (Pimephales promelas). Aquat Toxicol 86:361-369.
101. Witorsch RJ, Thomas JA. 2010. Personal care products and endocrine disruption: a critical review of the literature. Crit Rev Toxicol 40:1-30.
102. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. 2010. Deaths: final data for 2007. National Vital Statistics Reports.
103. Zheng M, Zhu W, Han Q, Xiao R-P. 2005. Emerging concepts and therapeutic implications of β-adrenergic receptor subtype signaling. Pharamcol Ther 108:257-268.
104. Zouhal H, Jacob C, Delamarche P, Gratas-Delamarche A. 2008. Catecholamines and the effects of exercise, training and gender. Sports Med 38:401-423.